Becton, Dickinson and Company $BDX Shares Purchased by Creekmur Asset Management LLC

Creekmur Asset Management LLC lifted its position in Becton, Dickinson and Company (NYSE:BDX) by 35.6% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,288 shares of the medical instruments supplier’s stock after acquiring an additional 338 shares during the quarter. Creekmur Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $222,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in BDX. Vanguard Group Inc. raised its position in Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after acquiring an additional 1,259,750 shares during the period. T. Rowe Price Investment Management Inc. raised its position in Becton, Dickinson and Company by 3.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock worth $2,880,510,000 after acquiring an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA raised its position in Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock worth $1,567,654,000 after acquiring an additional 667,957 shares during the period. JPMorgan Chase & Co. raised its position in Becton, Dickinson and Company by 7.6% during the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock worth $1,012,649,000 after acquiring an additional 312,124 shares during the period. Finally, Nordea Investment Management AB raised its position in Becton, Dickinson and Company by 0.4% during the second quarter. Nordea Investment Management AB now owns 3,365,509 shares of the medical instruments supplier’s stock worth $577,420,000 after acquiring an additional 12,602 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $178.77 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company has a fifty day simple moving average of $188.38 and a 200-day simple moving average of $183.17. The firm has a market capitalization of $51.24 billion, a price-to-earnings ratio of 32.15, a PEG ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion during the quarter. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Insider Activity

In related news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold a total of 1,895 shares of company stock valued at $358,995 over the last ninety days. Corporate insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of research analyst reports. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Argus upped their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $211.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, October 16th. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and an average target price of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.